122 related articles for article (PubMed ID: 16549281)
1. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size.
Schettini DA; Ribeiro RR; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Int J Pharm; 2006 Jun; 315(1-2):140-7. PubMed ID: 16549281
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
[TBL] [Abstract][Full Text] [Related]
3. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
4. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oral delivery of antimony from meglumine antimoniate/beta-cyclodextrin nanoassemblies.
Frézard F; Martins PS; Bahia AP; Le Moyec L; de Melo AL; Pimenta AM; Salerno M; da Silva JB; Demicheli C
Int J Pharm; 2008 Jan; 347(1-2):102-8. PubMed ID: 17656054
[TBL] [Abstract][Full Text] [Related]
6. Distribution of liposome-encapsulated antimony in dogs.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
[TBL] [Abstract][Full Text] [Related]
7. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Chapman WL; Hanson WL; Alving CR; Hendricks LD
Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
[TBL] [Abstract][Full Text] [Related]
8. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta-cyclodextrin conjugates.
Ribeiro RR; Ferreira WA; Martins PS; Neto RL; Rocha OG; Le Moyec L; Demicheli C; Frézard F
Biopharm Drug Dispos; 2010 Mar; 31(2-3):109-19. PubMed ID: 20014042
[TBL] [Abstract][Full Text] [Related]
9. The distribution of free and non-ionic vesicular sodium stibogluconate in the dog.
Collins M; Carter KC; Baillie AJ; O'Grady J
J Drug Target; 1993; 1(2):133-42. PubMed ID: 8069551
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.
Borborema SET; Osso Junior JA; Tempone AG; de Andrade Junior HF; do Nascimento N
Biomed Pharmacother; 2018 Jul; 103():1609-1616. PubMed ID: 29864949
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate.
Cruz A; Rainey PM; Herwaldt BL; Stagni G; Palacios R; Trujillo R; Saravia NG
J Infect Dis; 2007 Feb; 195(4):602-8. PubMed ID: 17230422
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation.
Phan G; Herbet A; Cholet S; Benech H; Deverre JR; Fattal E
J Control Release; 2005 Dec; 110(1):177-88. PubMed ID: 16257469
[TBL] [Abstract][Full Text] [Related]
13. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate.
Williams DM; Carter KC; Baillie AJ
J Drug Target; 1995; 3(1):1-7. PubMed ID: 7655816
[TBL] [Abstract][Full Text] [Related]
14. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.
Herman EH; Rahman A; Ferrans VJ; Vick JA; Schein PS
Cancer Res; 1983 Nov; 43(11):5427-32. PubMed ID: 6616474
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary delivery of insulin by liposomal carriers.
Huang YY; Wang CH
J Control Release; 2006 Jun; 113(1):9-14. PubMed ID: 16730838
[TBL] [Abstract][Full Text] [Related]
16. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
17. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
Padamwar MN; Pokharkar VB
Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
[TBL] [Abstract][Full Text] [Related]
18. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
[TBL] [Abstract][Full Text] [Related]
19. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo.
Sou K; Goins B; Takeoka S; Tsuchida E; Phillips WT
Biomaterials; 2007 Jun; 28(16):2655-66. PubMed ID: 17316790
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and local toxicity studies of a liposomal formulation for the novel local anaesthetic ropivacaine.
de Araujo DR; Cereda CM; Brunetto GB; Vomero VU; Pierucci A; Neto HS; de Oliveira AL; Fraceto LF; Braga Ade F; de Paula E
J Pharm Pharmacol; 2008 Nov; 60(11):1449-57. PubMed ID: 18957165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
